HeadSense
Noninvasive Multiparameter Brain Monitoring
Company Overview
Snapshot
Founded in April 2011, HeadSense operates with 11–50 employees. The company has secured funding across two rounds from three investors.
Business overview
HeadSense Medical develops noninvasive intracranial pressure (ICP) monitors designed to assist in the treatment of patients suffering from severe traumatic brain injury (TBI), stroke, and brain tumors. Its core product, the HeadSense ICP monitor, utilizes a headset-like disposable unit that continuously monitors ICP levels. The device emits an acoustic signal through the skull, which is then analyzed by a proprietary signal-processing algorithm to provide ICP readings in mmHg, with data displayable on tablets or smartphones. The company operates within the Health Tech & Life Sciences sector, specifically focusing on Digital Healthcare and Medical Devices, serving healthcare providers in geomarkets such as the United States, Germany, Israel, and Japan.
Strategic signal
In July 2013, HeadSense's intracranial pressure monitoring earbuds were highlighted by Medgadget for their potential to eliminate the need for invasive skull drilling. This news underscored the company's innovative approach to patient care and its commitment to developing less intrusive medical technologies, signaling a significant advancement in the field of neurology and medical monitoring.
Log in to access full profile ›Company Intelligence Q&A
- What is HeadSense's primary focus?
- HeadSense Medical is dedicated to developing noninvasive intracranial pressure (ICP) monitors for patients with severe traumatic brain injury (TBI), stroke, and brain tumors.
- When was HeadSense founded?
- HeadSense was founded in April 2011.
- Which investors participated in HeadSense's July 2013 funding round?
- In July 2013, HeadSense received funding from investors including GE Ventures and Pontifax.
- What is the core technology behind HeadSense's ICP monitor?
- The HeadSense ICP monitor uses an acoustic signal transmitted through the skull, which is then analyzed by a proprietary signal-processing algorithm to determine ICP levels in mmHg.
- Did HeadSense receive any non-equity funding?
- In November 2013, HeadSense secured a grant from the Office of the Chief Scientist.